Luly Jay R.
SEC CIK 1571211 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ENTA | ENANTA PHARMACEUTICALS INC | Pres, CEO, Dir | 878.0K | $256.1K | $3.05M | 30 | 2021-09-15 | 2026-02-12 |
Most active insiders at ENTA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Luly Jay R. | Pres, CEO, Dir | — | $67.5K |
| 2 | Or Yat Sun | CSO | — | $34.0K |
| 3 | Kieffer Tara Lynn | Chief Product Strategy Off | — | $30.0K |
| 4 | Luu Brendan | Chief Business Off | — | $19.8K |
| 5 | Trout Harry R. III | See Remarks | — | $13.0K |
| 6 | Rottinghaus Scott T. | Chief Medical Off | — | $11.4K |
| 7 | Capps Kathleen S. | See Remarks | — | $7,486 |
| 8 | Kowalsky Matthew Paul | CLO | — | — |
Transactions 30
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-13 | 2026-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | A - Grant | $0.00 | +20.0K | 878.0K | +2% | $0 |
| 2026-02-13 | 2026-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | F - Tax | $14.25 | -6,155 | 871.9K | -0.7% | -$87.7K | |
| 2025-12-05 | 2025-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | S - Sale | $14.23 | -4,743 | 858.0K | -0.5% | -$67.5K | |
| 2025-12-03 | 2025-12-01 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | F - Tax | $14.12 | -1,885 | 862.8K | -0.2% | -$26.6K | |
| 2025-02-14 | 2025-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | A - Grant | $0.00 | +25.5K | 872.1K | +3% | $0 | |
| 2025-02-14 | 2025-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | F - Tax | $5.59 | -7,484 | 864.7K | -0.9% | -$41.8K | |
| 2025-02-12 | 2025-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | P - Purchase | $5.69 | +45.0K | 846.6K | +6% | +$256.1K | |
| 2024-12-10 | 2024-12-06 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | S - Sale | $8.06 | -5,142 | 801.6K | -0.6% | -$41.4K | |
| 2024-12-03 | 2024-12-01 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | F - Tax | $8.60 | -3,829 | 806.8K | -0.5% | -$32.9K | |
| 2024-02-14 | 2024-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | F - Tax | $12.41 | -1,584 | 810.6K | -0.2% | -$19.7K | |
| 2024-02-14 | 2024-02-12 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | A - Grant | $0.00 | +5,400 | 812.2K | +0.7% | $0 | |
| 2023-12-06 | 2023-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | S - Sale | $9.63 | -7,230 | 806.8K | -0.9% | -$69.6K | |
| 2023-12-05 | 2023-12-01 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | F - Tax | $9.49 | -5,787 | 814.0K | -0.7% | -$54.9K | |
| DM | 2023-03-14 | 2023-03-13 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | S - Sale+OE | $45.16 | -27.9K | 837.0K | -3% | -$1.26M |
| D | 2023-03-14 | 2023-03-13 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $14.00 | +27.9K | 847.7K | +3% | +$390.8K |
| MA | 2023-02-15 | 2023-02-13 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | A - Grant | $0.00 | +52.1K | 840.4K | +7% | $0 |
| A | 2023-02-15 | 2023-02-13 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | F - Tax | $52.77 | -20.6K | 819.8K | -2% | -$1.09M |
| M | 2023-02-15 | 2023-02-13 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | A - Grant | $0.00 | +31.5K | 819.8K | +4% | $0 |
| 2023-02-15 | 2023-02-13 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | F - Tax | $52.77 | -20.6K | 799.2K | -3% | -$1.09M | |
| D | 2022-12-19 | 2022-12-19 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $27.58 | +14.5K | 788.3K | +2% | +$399.9K |
| DM | 2022-12-16 | 2022-12-16 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | S - Sale+OE | $44.72 | -30.0K | 773.8K | -4% | -$1.34M |
| DM | 2022-12-16 | 2022-12-16 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $14.10 | +30.0K | 790.0K | +4% | +$422.9K |
| 2022-12-05 | 2022-12-01 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | F - Tax | $44.33 | -5,659 | 773.8K | -0.7% | -$250.9K | |
| D | 2022-11-28 | 2022-11-23 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | A - Grant | $0.00 | +63.0K | 779.5K | +9% | $0 |
| M | 2022-02-15 | 2022-02-14 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO | A - Grant | $0.00 | +8,028 | 712.4K | +1% | $0 |
| 2022-02-15 | 2022-02-14 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO | F - Tax | $62.49 | -2,355 | 716.5K | -0.3% | -$147.2K | |
| D | 2022-01-18 | 2022-01-15 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | M - OptEx | $11.77 | +10.1K | 710.8K | +1% | +$118.4K |
| 2021-12-03 | 2021-12-01 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | F - Tax | $87.68 | -1,944 | 700.7K | -0.3% | -$170.4K | |
| D | 2021-11-23 | 2021-11-19 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | A - Grant | $0.00 | +25.7K | 702.7K | +4% | $0 |
| 2021-09-17 | 2021-09-15 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Pres, CEO, Dir | S - Sale | $59.06 | -4,516 | 677.0K | -0.7% | -$266.7K |
Purchase Sale Sale after option exercise All abbreviations